CAR-T Cells Engineered to Clear Alzheimer's Amyloid Plaques Show Promise in Mice
Scientists reprogrammed CD4+ T cells with amyloid-targeting CAR receptors, reducing brain plaques and reshaping CNS immunity in Alzheimer's mouse models.
Summary
Researchers at Washington University engineered CD4+ T cells with chimeric antigen receptors (CARs) derived from the Lecanemab antibody to target fibrillar amyloid-β plaques in Alzheimer's disease. In 5xFAD amyloidosis mice, these CAR-T cells localized to amyloid-rich sites in the dura, reduced dural amyloidosis, decreased parenchymal plaque burden, and recruited endogenous CD4+ T cells into the brain. A transient mRNA-based CAR approach also reduced astrogliosis and microgliosis while avoiding risks associated with permanently activated cells. The study establishes proof of concept that plaque-specific CD4+ CAR-T therapy can modify AD pathology and reshape the CNS immune landscape.
Detailed Summary
Alzheimer's disease (AD) affects millions globally, yet approved therapies — including antiamyloid antibodies like Lecanemab and Donanemab — offer only marginal cognitive benefit while carrying risks such as amyloid-related imaging abnormalities. This study explores a fundamentally different immunotherapeutic approach: engineering CD4+ T cells with chimeric antigen receptors (CARs) that directly recognize and respond to fibrillar amyloid-β plaques, bypassing the HLA-restricted antigen presentation that limits TCR-based strategies.
The team constructed multiple CAR variants using single-chain antibody fragments (scFvs) derived from Aducanumab and Lecanemab, each paired with either CD28 or 4-1BB costimulatory domains and the CD3ζ signaling region. Using a 58α⁻β⁻ NFAT-GFP reporter hybridoma system, they screened all constructs against monomeric, oligomeric, and fibrillar Aβ1–42. The Lecanemab-derived CAR with CD28 costimulation (Lec28z) emerged as the most potent, showing robust activation specifically in response to fibrillar amyloid and to brain extracts from 5xFAD mice — but not wild-type controls — confirming selectivity for plaque-associated antigen. Primary murine CD4+ T cells retrovirally transduced with Lec28z demonstrated activation-induced CAR internalization alongside upregulation of CD69 and CD25 upon fibril stimulation.
Adoptive transfer of Lec28z CD4+ CAR-T cells into 5xFAD mice produced striking in vivo results. CAR-T cells and co-recruited endogenous CD4+ T cells accumulated at arachnoid cuff exit (ACE) points — dural CSF exit sites recently identified as focal zones of dural amyloidosis. Six weeks post-transfer, treated animals showed significant reductions in dural amyloid burden. In the brain parenchyma and leptomeninges, CAR-T treatment increased CD4+ T cell presence and reduced plaque load, suggesting both direct clearance and indirect immune remodeling effects.
A critical safety innovation involved replacing stable retroviral transduction with transient mRNA-based CAR delivery. mRNA CAR-T cells achieved parenchymal plaque clearance comparable to stably transduced cells while also reducing markers of neuroinflammation — astrogliosis (GFAP) and microgliosis (Iba1) — without the risks posed by perpetually activated, cytotoxic-capable T cells. This transient approach also limits off-target autoimmune potential.
The study positions CD4+ CAR-T therapy as a potentially universal, HLA-independent immunotherapeutic platform for AD. Beyond direct plaque clearance, CD4+ T cells may orchestrate beneficial microglial reprogramming and neuroprotective cytokine environments — effects not achievable with passive antibody infusion. While the findings are restricted to mouse models with caveats around interspecies translation, they establish a compelling rationale for advancing cellular immunotherapy into the AD therapeutic pipeline.
Key Findings
- Lec28z CAR (Lecanemab scFv + CD28 domain) selectively activated by fibrillar amyloid-β, not monomers or oligomers.
- CAR-T cells concentrated at dural ACE points and significantly reduced dural amyloid burden in 5xFAD mice.
- Treatment recruited endogenous CD4+ T cells into brain parenchyma and leptomeninges, amplifying immune response.
- Transient mRNA-based CAR-T approach cleared parenchymal plaques and reduced astrogliosis and microgliosis.
- CD4+ CAR-T strategy bypasses HLA restriction, offering a potential universal therapeutic platform for Alzheimer's.
Methodology
Researchers engineered CAR constructs using Aducanumab- and Lecanemab-derived scFvs with CD28 or 4-1BB costimulatory domains, validated in 58α⁻β⁻ NFAT-GFP reporter hybridomas and primary murine CD4+ T cells. Lec28z CAR-T cells were adoptively transferred into 5xFAD amyloidosis mice at 4.5 months; dural, parenchymal, and leptomeningeal pathology was assessed at 6 months. A separate cohort received mRNA-encoded CAR-T cells to evaluate transient versus stable expression.
Study Limitations
All experiments were conducted in 5xFAD mice, a highly aggressive familial AD model that may not recapitulate the pathology of sporadic human AD. The durability of CAR-T effects, potential for off-target autoimmune responses, and the challenge of CNS penetration in humans remain unaddressed. Human CD4+ CAR-T behavior, safety, and efficacy will require extensive validation before clinical application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: